Wolverine blend (BPC/TB)
BPC-157 + TB-500
The 'Wolverine' blend combines BPC-157 and TB-500, and is marketed in fitness and injury-recovery circles for rapid healing. The pairing itself has not been studied.
Regulatory status: Not an FDA-approved drug. BPC-157 was reviewed by the FDA's Pharmacy Compounding Advisory Committee, which found insufficient safety and effectiveness evidence; TB-500 has no therapeutic approval anywhere.
Default vial
10 mg
Default mix
2 mL
Reported range
250–500 mcg of blend
Draw (U-100)
10 u
Even 50/50 split of BPC-157 and TB-500 in one vial, so a 500 mcg draw is ~250 mcg of each. Common injury-recovery pairing.
What it is
- The simplest of the common blends — two peptides — but still an unapproved compounded mixture.
- Ratios and doses vary by vendor; only a Certificate of Analysis confirms content.
- Marketed heavily in fitness communities, largely outside clinical oversight.
- Frequently labelled 'research use only' despite being sold for human injection.
How it is described to act
- 1
Injected subcutaneously in practice; no studied combination regimen exists.
- 2
Each peptide distributes according to its own properties; there are no combined pharmacokinetic data.
- 3
BPC-157 is proposed from rodent studies to accelerate tendon, ligament and gut healing; TB-500's proposed cell-migration and angiogenesis role is inferred from thymosin beta-4 biology.
- 4
The claim of synergistic faster healing is an extrapolation from separate animal studies, not a tested finding.
What the research has looked at
Component-level literature
- BPC-157 preclinical and organoprotective reviews (Gut and Liver, 2020; Curr Pharm Des, 2020) describe rodent findings.
- The FDA's 2026 briefing document found insufficient clinical safety and effectiveness evidence for BPC-157 and documented adverse-event reports.
- Thymosin beta-4 preclinical reviews (2018) describe tissue-repair roles for the parent protein.
No blend-level evidence
- Searches for the pairing return studies of each peptide separately; no record of the combination as a product was located.
Strength of evidence: Preclinical evidence only
No human data exist for the combination, and the component evidence is mostly rodent-based.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- Injection-site reactions appear among the adverse events reported to the FDA for BPC-157.
- There are no combined pharmacokinetic or toxicity data for any of these blends, so interaction risk is unquantified.
- The FDA's 2026 compounding-committee briefing on BPC-157 documented adverse-event reports and gaps in impurity characterisation for that single peptide.
- Sterility, identity and concentration of multi-peptide compounded vials vary by supplier; only a current third-party Certificate of Analysis can confirm what a vial actually contains.
References
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
Wolverine blend (BPC/TB) questions people ask
How do you reconstitute Wolverine blend (BPC/TB)?
A common starting point for a 10 mg vial of Wolverine blend (BPC/TB) is 2 mL of bacteriostatic water, which gives 5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of Wolverine blend (BPC/TB) is one dose?
At 5 mg per mL, that works out to about 10 units on a U-100 insulin syringe for a 500 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for Wolverine blend (BPC/TB)?
Published and community sources describe 250–500 mcg of blend, subcutaneous, every day, typically run 6 weeks on and 2 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should Wolverine blend (BPC/TB) be stored?
Lyophilized Wolverine blend (BPC/TB) vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.